The Stephenson Global Prize and Stephenson Global Scholar Grants calls for nominations, letters of intent

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

Approximately 21 years ago, I had the privilege of working and helping to pass Proposition 71, which authorized $3 billion dollars in state bonds to fund stem cell research in California.

CPRIT approves more than $15M in new funding for cancer research and recruitment

The governing board of the Cancer Prevention and Research Institute of Texas met in Austin and approved more than $15 million in CPRIT Scholar recruitment grants to bring five new cancer scientists to four Texas research institutions.

February 20, 2026

Vol.52 No.07

In Brief

Indiana University receives $5M grant to expand breast cancer diagnosis, care in Kenya

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center has been awarded a $5 million grant from the Pfizer Foundation to expand access to timely breast cancer diagnosis, treatment, and care in Kenya.

February 20, 2026

Vol.52 No.07

Drugs & Targets

FDA approves pancreatic cancer device

FDA approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields, to the abdomen.

February 20, 2026

Vol.52 No.07

Podcast

Lowy fields questions about peer review at inaugural meeting of the new NCAB ad hoc working group

With NCI Director Anthony Letai in Milan supporting his daughter, Julie, at the 2026 Winter Olympics, Douglas R. Lowy, principal deputy director of NCI, took on the job of delivering detailed remarks and fielding questions at the inaugural meeting of the NCAB’s ad hoc working group on Extramural Research Concepts and Programs.

February 18, 2026

Clinical Roundup

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives.

February 13, 2026

Vol.52 No.06

The Stephenson Global Prize and Stephenson Global Scholar Grants calls for nominations, letters of intent

YOU MAY BE INTERESTED IN

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

CPRIT approves more than $15M in new funding for cancer research and recruitment

Indiana University receives $5M grant to expand breast cancer diagnosis, care in Kenya

FDA approves pancreatic cancer device

Lowy fields questions about peer review at inaugural meeting of the new NCAB ad hoc working group

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Renew today!

Subscriber content

Never miss an issue!

Login